Dr Reddy's Q2FY27 Results: Earnings call scheduled for Oct 23 at 7:30 pm

1 min read | Published on 07 Oct 2026, 02:50 PM |Updated on 07 Oct 2026, 02:50 PM

Reviewed by

Anirudha BScanX News Team

Add as a preferred
source on Google

Key Highlights

Dr. Reddy's Laboratories will release Q2FY27 results on October 23, 2026
Earnings call scheduled for 19:30 pm IST (10:00 am ET) on the same day
Audio recording and transcript of the call will be available on the company website
Registration for the webinar is mandatory for participants

*this image is generated using AI for illustrative purposes only.

Dr. Reddy's Laboratories will announce its financial results for the quarter and six months ended September 30, 2026 on Friday, October 23, 2026. The company has scheduled an earnings call for the same day to discuss its performance.

Earnings call schedule

The management team will host a webinar to address investor queries regarding the quarterly results. The session is slated for 19:30 pm IST, which corresponds to 10:00 am ET. Participants are required to pre-register via the company's official website to access the live stream.

Key event details

The following table outlines the timeline and medium for the announcement and subsequent interactions:

Event	Date and Time	Medium
Release of financial results	Friday, October 23, 2026, after Board Meeting	Stock Exchange, Media, Company Website
Press Meet Presentation	Available post-release	Company Website
Earnings Call	Friday, October 23, 2026 at 19:30 pm IST / 10:00 am ET	Hosted by Company (Webinar)
Audio and Transcript	Available post-call	Stock Exchange, Company Website

Access and registration

Investors and media personnel can register for the earnings call through the provided link on the company's website. Following the conclusion of the call, both the audio recording and the written transcript will be made available on Dr. Reddy's corporate site for public review.

Historical Stock Returns for Dr Reddys Laboratories

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.74%	-4.22%	+4.18%	-1.54%	-3.96%	+20.96%

How might Dr. Reddy's Q2 FY2026 performance influence its strategic positioning in the US generic market compared to competitors?

What specific regulatory or pricing headwinds in key international markets could impact the company's revenue guidance for the remainder of the fiscal year?

Will the upcoming earnings call reveal new capital allocation priorities, such as increased R&D spending on biosimilars versus share buybacks?

Dr Reddys Laboratories

View Company Insights

View All News

Dr Reddy's Labs subsidiary receives $32,350 IRS penalty for tax error

1 min read | Published on 03 Oct 2026, 05:23 PM |Updated on 03 Oct 2026, 05:23 PM

Reviewed by

Suketu GScanX News Team

Add as a preferred
source on Google

Key Highlights

Dr Reddy's Laboratories' US subsidiary DRL Inc received a $32,350.20 IRS penalty
Penalty issued for misclassification of fiscal year reference in tax payment
Transcript dated September 25, 2026, was received by the subsidiary on October 2, 2026
Company states no material impact on financials or operations from the fine

*this image is generated using AI for illustrative purposes only.

Dr Reddy's Laboratories reported that its step-down wholly owned subsidiary, Dr. Reddy's Laboratories, Inc. (DRL Inc), received a final transcript from the Internal Revenue Service (IRS) levying a penalty of $32,350.20.

The notice was issued by the Department of the Treasury, Internal Revenue Service, Cincinnati, OH, US, with the transcript dated September 25, 2026, and received by DRL Inc on October 2, 2026. The penalty stems from a misclassification of the fiscal year reference at the time of tax payment.

Regulatory disclosure details

The intimation was filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III Para A Sub Para 20. The company clarified the nature of the action and its potential impact on the listed entity.

Parameter	Details
Authority	Department of Treasury, Internal Revenue Service, Cincinnati, OH, US
Penalty Amount	$32,350.20
Reason	Misclassification of fiscal year reference during tax payment
Date of Receipt	October 2, 2026
Impact on Company	No material impact on financials, operations, or other activities

Operational and financial impact

Dr Reddy's Laboratories stated that based on its evaluation, the penalty has no material impact on the financials, operations, or other activities of the company. The amount is immaterial relative to the scale of the pharmaceutical major's global operations, which includes significant revenue streams from the United States market.

The filing was signed by K Randhir Singh, Company Secretary, Compliance Officer, and Head-CSR, on October 3, 2026.

Historical Stock Returns for Dr Reddys Laboratories